All In Biotech

Drug Trial Radar · NCT04446351

Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors

A Phase 1 First-Time-in-Human, Open-Label Study of GSK6097608 Administered as Monotherapy and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

Last checked: Nov 19, 2026Latest source record: Oct 27, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

107

Actual

Start

Jun 25, 2020

Primary completion

Dec 31, 2026

Study completion Dec 31, 2026

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
Collaborators
23andMe, Inc.; iTeos Therapeutics
First posted
Jun 24, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This first-time-in-human (FTIH) study will evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary clinical activity of escalating doses of GSK6097608 given as monotherapy and in combination with dostarlimab in participants with advanced solid tumors. In addition, dostarlimab will be given as monotherapy (Arm D); and in combination with belrestotug (Arm E); and with GSK6097608 + belrestotug (Arm F) in Japanese and Chinese participants. The study may assess the PK/PD cohorts for Arm E and/or Arm F in participants outside of China and Japan. Additionally, dostarlimab will be given in combination with cobolimab in Japanese participants. Drug name mentioned as belrestotug, GSK4428859A and EOS884448 are interchangeable for the same compound. In the rest of the document, the drug will be referred to as belrestotug.

Conditions

  • Neoplasms

Interventions

  • GSK6097608Drug

    GSK6097608 will be administered as an IV infusion.

  • DostarlimabDrug

    Dostarlimab will be administered as an IV infusion.

  • CobolimabDrug

    Cobolimab will be administered as an IV infusion.

  • BelrestotugDrug

    Belrestotug will be administered as an IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with dose-limiting toxicities (DLTs)Time frame: Up to Day 21
  2. Number of participants with adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to 2 years

Locations

11 sites in 4 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Los Angeles, California

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Dallas, Texas

  • GSK Investigational Site

    Houston, Texas

  • GSK Investigational Site

    San Antonio, Texas

  • GSK Investigational Site

    Ottawa, Ontario, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Chiba, Japan

  • GSK Investigational Site

    Tokyo, Japan

  • GSK Investigational Site

    Seoul, South Korea

  • GSK Investigational Site

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.